Welcome to
Mesothelioma Options

We provide help for those with Mesothelioma

Globe 1
Nationwide Reach
Cases successfully handled in all 50 states
Recovered 1
$600 Million
Won and recovered for clients and families

Request a Free Case Review

No obligation. Speak directly to our compassionate legal-medical advocates.

For more than 25 years, the Steinberg Law Group has dedicated its practice to representing individuals and families affected by mesothelioma caused by asbestos exposure. Led by partners Robert L. Steinberg and Alex J. Steinberg, the firm has recovered hundreds of millions of dollars on behalf of its clients.

As a national firm with offices across the country, the Steinberg Law Group brings experience and resources to every case it handles.

The firm understands the profound impact a mesothelioma diagnosis has on its clients and their loved ones. Its mission is to pursue the accountability and compensation they deserve, guiding them through every step of the legal process with the attention and dedication their cases demand.

robert steinberg

Partner

alex steinberg

Partner

Treatment plans depend on the type, stage, and cell type of mesothelioma. A multidisciplinary team of specialists works together to determine the best course of action for each patient.

surgical

Procedures range from lung-sparing pleurectomy/decortication (P/D) to cytoreductive surgery (CRS) with HIPEC for peritoneal cases. Surgery aims to remove visible tumor and is most effective for early-stage epithelioid disease.

chemo

First-line options include platinum-based chemotherapy, dual immunotherapy (Opdivo + Yervoy), and the FDA-approved chemo-immunotherapy combination with Keytruda. Treatment choice depends on cell type and patient fitness.

radiation

Used primarily for symptom relief and pain management, radiation targets specific tumor deposits. Its role is limited by the sensitivity of surrounding organs but can provide meaningful palliative benefit.

clinical

Clinical trials have transformed mesothelioma treatment more in the past six years than in the previous thirty. Trial enrollment offers access to cutting-edge therapies, especially at the second-line where no approved standard exists.